AZ12601011
Code | Size | Price |
---|
TAR-T10426-50mg | 50mg | £1,099.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10426-100mg | 100mg | £1,500.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor (IC50: 18 nM; Kd: 2.9 nM) with inhibitory to mammary tumor growth. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting TGFBR1, ALK4, and ALK7.
CAS:
T10426
Formula:
C19H15N5
Molecular Weight:
313.36
Pathway:
Tyrosine Kinase/Adaptors; Angiogenesis
Purity:
0.98
SMILES:
C1(C2=NC=CC=C2)=NC(N3C=CC4=C3C=CN=C4)=C(CCC5)C5=N1
Target:
ALK
References
1. Spender LC, et al. Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor ?Superfamily Type 1 Receptors. Mol Pharmacol. 2019 Feb;95(2):222-234.